Efficacy and Safety Analysis of Oxaliplatin-based Chemotherapy for Advanced Gastric Cancer

Abstract

Abstract. Background: Significant efficacy of oxaliplatinbased chemotherapy has been demonstrated for advanced gastric cancer (AGC).Gastric cancer (GC) is the fourth most frequent malignant tumor and the second most common cause of tumor death in the world (1). Recurrent GC after curative resection and initially unresectable metastatic GC (advanced GC; AGC) are treated with systemic chemotherapy (CT), that can prolong survival and maintain quality of life. For the initial CT, combination consisting of fluorouracil or fluoropyrimidine and platinum has been demonstrated to be effective. The triplet regimen including fluoropyrimidine, platinum and epirubicin is often used in European countries (2). Effectiveness of a triplet of docetaxel, cisplatin and fluorouracil has been shown in the United States (3). The standard therapy for patients with AGC in Japan has been a combination of the oral fluoropyrimidine S-1 and cisplatin (SP) based on the results of the phase 3 SPIRITS study (4). Another fluoropyrimidine, capecitabine, has also been shown to be effective for AGC in combination with cisplatin (5).Oxaliplatin has also been employed for systemic CT for AGC in combination with fluorouracil or fluoropyrimidine 2663

Sorting nexin-1 is a candidate tumor suppressor and potential prognostic marker in gastric cancer

“…5-Fu and oxaliplatin are two of the most effective anticancer regimens in the chemotherapy against numerous solid tumors ( Graham, Mushin & Kirkpatrick, 2004 ; Longley, Harkin & Johnston, 2003 ). They are also the two common regimens for the treatment of patients with gastric cancer ( Inadomi et al, 2017 ; Li et al, 2010 ). In this study, we found that knockdown of SNX1 promoted cell proliferation, inhibited cell apoptosis in 5-Fu and oxaliplatin treated cells ( Fig.…”

AT-rich interactive domain1A determines sensitivity to oxaliplatin in gastric cancer cells

“…It is reported in the literature that ARID1A frequently undergoes gene mutations in various tumors, suggesting that it may be a potential tumor suppressor gene ( 23 , 24 ). Oxaliplatin based chemotherapy plays a significant role in the treatment of gastric cancer, but many cancer patients are resistant to platinum drugs, which seriously reduces the efficacy of platinum drugs and limits their clinical application ( 25 ). The high ARID1A mutation rate in gastric cancer might be the reason for the platinum resistance.…”

Synthesis and characterization of thiocarbonato-linked platinum(iv) complexes

“…1–8 It is applied in the treatment of colorectal, pancreatic and gastric cancer, alone or in combination with other drugs. 9–16 As part of the third generation of platinum drugs, oxaliplatin is armed with the bidentate ligand R , R -DACH and the chelating oxalate ligand, both increase its kinetic stability. 17 After hydrolysis of the leaving group, the activated platinum( ii ) complex forms adducts with two adjacent guanines or guanine and adenine in DNA strands, thus interfering with DNA replication and transcription and inducing cell death.…”